Clinical trial · Interventional
Symbiotics to Prevent Postoperative Infection in Colorectal Cancer
Change in Incidence of Surgical Site Infection After Resection of Colorectal Cancer Between Patients Receiving a Symbiotic Compound and Patients Receiving a Placebo.
NCT02571374CI-TRIAL-00019404unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a double blind randomized trial in which patients with colorectal cancer undergoing surgery will be selected to receive either a symbiotic formulation or placebo. The researchers will compare incidence of surgical site infection between the study groups.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Surgical Site Infection | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| placebo group | Dietary Supplement | — | UNRESOLVED |
| symbiotic group | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- symbiotic group
- description
- Symbiotic group
- interventionNames
- Dietary Supplement: symbiotic group
- type
- PLACEBO_COMPARATOR
- label
- placebo group
- description
- placebo group
- interventionNames
- Dietary Supplement: placebo group
Primary outcomes (1)
- measure
- Number of participants with colorectal cancer on symbiotic to prevent postoperative infection
- timeFrame
- 1 month
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 85 Years
Show eligibility criteria text
Inclusion Criteria: * Adults between 18 and 85 years old; * Colorectal cancer patients. * Ability to understand and signing the informed consent Exclusion Criteria: * Pregnancy (early diagnosis) * Reduced intellectual level that could prevent proper understanding of the objectives of the study * Patients with rectal cancer undergoing neoadjuvant treatment (chemotherapy and radiotherapy) * Use of products with prebiotic, probiotic and / or symbiotic function or fiber module; by more than 3x a week * Refusal to participate and / or to sign the Consent Form Free and Clear
References
Publications (0)
Data not yet available
No reference posted for this study.